Peto writes that "any competent trial statistician" would back his conclusions and says that Vytorin's makers, Merck and Schering-Plough, do not pay his salary and had no impact on the decision to conduct his analysis or on how the analysis was conducted (see Peto's letter).

FORBES: Magazine Article

Peto writes that he and his colleagues at CTSU take no honoraria, consultancy fees or other payments, although companies occasionally pay for their travel accommodations.

FORBES: Magazine Article